Context: Activating antibodies directed at the extracellular calcium-sensing receptor (CaSR) have been described in autoimmune hypoparathyroidism in the setting of isolated hypoparathyroidism or autoimmune polyglandular syndrome type 1.
| INTRODUC TI ON
Blizzard and coworkers were the first to demonstrate anti-parathyroid antibodies in patients with idiopathic hypoparathyroidism, although the parathyroid antigen(s)'s identity was uncertain. 1 Subsequently, the extracellular calcium-sensing receptor (CaSR) was identified as a target of anti-parathyroid antibodies. [2] [3] [4] Later, inactivating antibodies against the receptor were demonstrated in four patients with PTH-dependent hypercalcaemia, three of whom also had hypocalciuria. 5 This clinical presentation is similar to that of familial hypocalciuric hypercalcaemia (FHH), which is, in most cases, caused by inactivating CaSR mutations. 6 CaSR antibody-mediated inhibition of CaSR activity in two of these cases was demonstrated
by showing antibody-mediated inhibition of Ca 2+ -elicited activation | 215
of inositol phosphate (IP) accumulation and extracellular-regulated kinases 1 and 2 (ERK1/2) activity. 5 The same group then demonstrated activating anti-CaSR antibodies in two patients with autoimmune hypoparathyroidism. 7 These patients' clinical presentation resembled that of autosomal dominant hypoparathyroidism caused by activating CaSR mutations. 6 While very uncommon, additional examples of inactivating or activating CaSR antibodies have been reported in PTH-dependent hypercalcaemia or hypocalcaemia, respectively. [8] [9] [10] [11] In one case with inactivating antibodies, the hypercalcaemia was steroid responsive, while in a second, it was not. 8, 9 Here, we report a unique case of severe hypoparathyroidism caused by activating antibodies to the CaSR, which was responsive to immunosuppressive therapy.
| MATERIAL S AND ME THODS

| Patient clinical history
A 34-year-old Caucasian female with a past medical history of hypertension, arthritis, and obesity presented to our institution with perioral and bilateral hand numbness, tingling, and muscle cramps.
Four months prior, she was seen at an outside hospital emergency at 48 pg/mL (normal range, 14-72 pg/mL), magnesium was 1.5 mg/ dL (normal range, 1.8-2.4 mg/dL), and ionized calcium was 3.2 mg/ dL (normal range, 4.6-5.4 mg/dL). Intravenous calcium gluconate and magnesium sulphate was administered, and she was discharged on high dose calcium carbonate (1500 mg three times daily) and magnesium oxide (400 mg daily). The following day she presented to the same ER with similar symptoms. Total serum calcium was 7.5 mg/ dL, and magnesium was 1.6 mg/dL. She received intravenous magnesium and was discharged with nephrology follow-up.
After nephrology evaluation, she was initiated on calcitriol (0.25 µg twice daily) and ergocalciferol weekly; calcium carbonate and magnesium oxide were continued. Outpatient laboratory studies 2 days after the patient's visit showed total serum calcium of 6.4 mg/dL, potassium 3.5 mg/dL (normal range, 3.5-5.1 mg/dL), and magnesium of 1.5 mg/dL. PTH was 30.5 pg/mL, and 25-hydroxyvi- 
| CaSR immunoprecipitation assays
Calcium-sensing receptor immunoprecipitation assays for detecting CaSR antibodies were carried out as before. 12 The patient's pre-and post-immunosuppressive treatment serum samples (n = 2), and previously studied healthy control sera (n = 10), 12 were stored at −80°C. A CaSR antibody index for each serum in the immunoprecipitation assay was calculated as the densitometry value of the tested serum/mean densitometry value of 10 control sera. The upper normal limit for the assay was calculated using the mean CaSR antibody index +3 SD of these control individuals. A CaSR antibody index above the upper normal limit was designated as positive for CaSR antibody reactivity. All assays were run blinded to avoid operator bias.
| Measurement of CaSR-stimulated inositol-1-phosphate accumulation
The CaSR's response to Ca 2+ was assessed in HEK293 cells stably expressing the receptor (HEK293-CaSR) by measuring intracellular inositol-1-phosphate (IP1) accumulation using a specific IP-1 ELISA (CIS Bio International, Gif-sur-Yvette, France). 11 The IP-1 ELISA is highly specific, with no cross-reactivity to myo-inositol, IP2, IP3 or IP4. Results obtained using this assay are comparable to those measuring inositol phosphate by tritium-labelling.
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Monolayer HEK293-CaSR cells were cultured as in 24-well plates.11 The cells were washed with serum-free medium and then Ca 2+ -free assay buffer containing 10 mmol/L lithium chloride. 11 Cells were preincubated for 10 minutes at 37°C with duplicate IgG samples
(1:100 in assay buffer) prepared from the patient's and control sera. 
| Measurement of CaSR-stimulated ERK1/2 phosphorylation
The CaSR's response to Ca 2+ was also assessed by measuring phosphorylation of extracellular signal-regulated kinases 1 and 2 
| IgG and CaSR antibody purification
IgG was isolated from sera using protein G-Sepharose 4 Fast Flow 
| Statistical analyses
Statistical analyses were performed using Student's unpaired t tests.
P values < 0.05 (two-tailed) were regarded as statistically significant.
| RE SULTS
| Response of severe hypocalcaemia and acquired hypoparathyroidism to immunosuppressive therapy
The patient had no previous personal or family history of abnormalities of calcium or magnesium metabolism, hence ruling out a genetic cause of hypoparathyroidism; therefore, an autoimmune basis was considered. Antibodies to PTH were assayed, but were not detected.
The possibility that CaSR-activating antibodies were causing hypocalcaemia and low PTH was investigated since such autoantibodies have been reported previously in individuals with autoimmune hypoparathyroidism. [7] [8] [9] [10] [11] While testing for antibodies was underway, she was started on immunosuppressive treatment with prednisone 60 mg and azathioprine 150 mg daily, given the severity of her clinical presentation and clinical course. In addition, she continued to receive calcitriol and oral calcium and magnesium supplements. This approach was based on the assumption that reducing the titre of such antibodies might be beneficial in this severe case of hypoparathyroidism unresponsive to aggressive therapy of calcium and magnesium supplementation. Moreover, in a previously described case of inactivating CaSR antibodies as the cause of PTH-dependent, hypocalciuric hypercalcaemia, the patient's hypercalcaemia remitted during glucocorticoid therapy. 8 Furthermore, given the morbidities associated with long-term steroid use, including, but not limited to, diabetes mellitus, and avascular necrosis of the hip, azathioprine was added as a steroid-sparing agent, since it was anticipated that the patient would require long-term immunosuppression based on the earlier report. 8 Azathioprine is one of the oldest immunosuppressive drugs in continuous use. It blocks the de novo pathway of purine synthesis, and its relative specificity for lymphocytes results from their lack of a salvage pathway. 14 Azathioprine has been used as a steroid-sparing agent for the long-term maintenance therapy for autoimmune diseases, such as lupus nephritis and pauci-immune glomerulonephritis.
15,16
The patient's total and ionized calcium, magnesium and phosphate levels prior to and subsequent to treatment prednisone and azathioprine are shown in Figure 1 . Forty-eight hours after starting immunosuppressive therapy, she no longer required intravenous calcium supplementation and within four days she did not require intravenous magnesium. All oral supplementation was continued. In addition, her PTH level was 2.4 pg/mL and 2.0 pg/mL on hospital day 1 and day 4, respectively, while receiving calcitriol, and increased to 7.6 pg/mL after treatment with immunosuppressants.
The patient was discharged home 36 days after the initial presentation at our institution on prednisone 60 mg daily and azathioprine 150 mg daily, and calcitriol 1.5 µg daily, as well as calcium and magnesium supplements. The detailed time course of prednisone dose and serum calcium concentration after this discharge is shown in Table 1 . Initially, prednisone was tapered down to 20 mg daily as an outpatient. Thirteen days later, the patient was re-hospitalized for symptomatic hypocalcaemia. Total serum calcium was 6.8 mg/dL, magnesium 1.3 mg/dL, phosphate 4.3 mg/dL, and PTH 2.2 pg/mL.
The dose of prednisone was increased back to 60 mg and calcitrol to 2.0 µg daily. Within 3 days, total serum calcium levels trended up and peaked at 13.5 mg/dL 6 days after the dose of prednisone was increased. She developed acute kidney injury (AKI) due to hypercalcaemia, which resolved with intravenous fluid and withholding calcitriol and calcium supplements. She was restarted and discharged on a lower dose of calcitriol (0.5 µg daily). Following the next taper to 40 mg prednisone, the patient relapsed again with total serum calcium at 6.9 mg/dL (Table 1) . Serum calcium levels normalized when the dose of prednisone was increased back to 60 mg. Calcitrol was increased to 0.5 µg twice daily.
Again, the patient became overtly hypercalcaemic and developed AKI due to concurrent increases in calcitriol and calcium supplements with the relapse. The hypercalcaemia resolved after calcitriol and calcium supplements were withheld briefly. Given the severity of the patient's hypocalcaemia, her multiple ER visits and hospitalizations, and the need for daily intravenous calcium infusion to maintain serum calcium within the desired range, an attempt was not made to taper off calcitriol after immunosuppression was initiated. In our view, the benefit of continuing calcitriol was felt to outweigh any risk of ongoing treatment. Since the patient developed hypocalcaemia when the prednisone dose was lowered despite the use of azathioprine as a potential steroid-spring agent, azathioprine was tapered off as it did not seem to have an effect on serum calcium levels.
During the next taper in prednisone dose from 60 mg at four months after initial discharge to 0 mg at 7 months after initial discharge, serum calcium concentrations remained in the range of 8-9 mg/dL ( 
| Detection of CaSR antibodies
| CaSR-modulating effects of the patient's IgG
To determine the effects of the CaSR antibodies on CaSR function, 
| D ISCUSS I ON
CaSR antibodies occur in a substantial number of patients with idiopathic hypoparathyroidism or hypoparathyroidism as part of autoimmune polyglandular syndromes. 2, 7, 11, 12, 17, 18 In most cases, the biological activity of the CaSR antibodies has not been tested or was negative. Occasional patients have had biologically active caSR antibodies. 7, 11 Here, we describe the fifth case of autoimmune TA B L E 1 Prednisone dose and total serum calcium levels over time As in two earlier cases, 7 residual parathyroid function in our case was documented despite the CaSR antibodies. In the first such report, 7 the hypoparathyroidism remitted spontaneously in one case and normal appearing parathyroid tissue was documented in the second during incidental thyroid surgery. 7 In the present case, the hypocalcaemia improved dramatically with immunosuppressive therapy and relapsed when the dose of prednisone was decreased. Although antibody titres were not measured during the relapse, the presumption is antibody titres were reduced with high dose steroids as hypocalcaemia resolved within 48 hours after dose increased similar to her prior hospitalization. As noted above, hypoparathyroidism caused by activating CaSR antibodies could potentially be tested for residual parathyroid function using a calcilytic. In contrast to a CaSR antagonist in this setting, a
CaSR activator is a potential therapy in AHH, by counteracting the blocking effect of the CaSR antibody, thereby restoring normocalcemia. In fact, the calcimimetic, cinacalcet, ameliorated the hypercalcaemia in a case of AHH. 24 It will be interesting to determine the effects of cinacalcet in additional cases of AHH. Notably, cinacalcet has also been shown to improve the hypercalcaemia in several cases of FHH caused by inactivating CaSR mutations. 6 F I G U R E 2 Analysis of patient CaSR antibodies. Serum samples from the patient (n = 2), and healthy controls (n = 10) were analysed for CaSR antibodies in CaSR immunoprecipitation assays at a 1:100 dilution. The patient's serum samples were taken before and after prednisone and azathioprine treatment. The CaSR antibody index (± SD) of the pre-treatment sample is shown in panel (A) next to the CaSR antibody index value (± SD) for the patient's post-treatment serum sample, each representing the mean of three experiments. The mean CaSR antibody index (± SD) of the group of 10 healthy control sera is shown also. The upper limit of normal for the CaSR immunoprecipitation assay was a CaSR antibody index of 2.75. Serum samples from the patient (pre-treatment) and healthy controls were In summary, this is the first demonstration of CaSR antibody-mediated hypoparathyroidism responsive to immunosuppressive therapy, adding to the evidence of the role of activating CaSR antibodies in hypoparathyroidism.
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